AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Study of Intragastric pH Profile After 5 Days Pantoprazole 40 mg iv Followed by Oral Esomeprazole 40 mg po or Oral Pantoprazole 40 mg po
Phase 4
Completed
- Conditions
- Healthy
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2011-01-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 40
- Registration Number
- NCT00206050
- Locations
- 🇺🇸
Research Site, Oklahoma City, Oklahoma, United States
Acid-Associated Heartburn Symptoms and Dose of Esomeprazole
Phase 4
Completed
- Conditions
- Heartburn
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2010-11-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 330
- Registration Number
- NCT00206024
- Locations
- 🇵🇷
Research Site, Ponce, Puerto Rico
Long Term Open Follow-up With H376/95 vs. Warfarin
Phase 2
Terminated
- Conditions
- Stroke Prevention in Patients With Atrial Fibrillation
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2010-11-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 220
- Registration Number
- NCT00206063
- Locations
- 🇬🇧
Research Site, Newcastle, United Kingdom
Melagatran/Ximelagatran Versus Enoxaparin for the Prevention of Venous Thromboembolic Events
Phase 3
Terminated
- Conditions
- Thromboembolism
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2010-11-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 3300
- Registration Number
- NCT00206089
- Locations
- 🇨🇭
Research Site, Zurich, Switzerland
A Study of the Cataractogenic Potential of Seroquel and Risperdal in the Treatment of Participants With Schizophrenia or Schizoaffective Disorder
Phase 4
Completed
- Conditions
- SchizophreniaSchizoaffective Disorder
- Interventions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2013-01-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1098
- Registration Number
- NCT00206102
- Locations
- 🇺🇸
Research Site, Richmond, Virginia, United States
Seroquel in Bipolar Depression Versus Lithium
Phase 3
Completed
- Conditions
- Bipolar DisorderBipolar DepressionDepression
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2013-01-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 672
- Registration Number
- NCT00206141
- Locations
- 🇺🇦
Research Site, Vinnitsa, Ukraine
SR-Registration Study 1, ROW: Efficacy and Safety of Seroquel® in the Treatment of Patients With Schizophrenia
Phase 3
Completed
- Conditions
- Schizophrenic Disorder
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2013-01-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 535
- Registration Number
- NCT00206115
- Locations
- 🇿🇦
Research Site, Pretoria, South Africa
A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and 2 x 80/4.5 μg Bid With Formoterol Turbuhaler® 2 x 4.5 μg Bid and Placebo in Patients With COPD
Phase 3
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2009-03-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1600
- Registration Number
- NCT00206167
- Locations
- 🇷🇴
Research Site, Iasi, Romania
NEXIUM® in the Treatment of Moderate and Severe Erosive Esophagitis
Phase 4
Completed
- Conditions
- Erosive EsophagitisReflux EsophagitisGastroesophageal Reflux Disease
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2009-03-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 120
- Registration Number
- NCT00206180
- Locations
- 🇺🇸
Research Site, Milwaukee, Wisconsin, United States
A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and Symbicort® pMDI 2 x 80/4.5 μg Bid With Formoterol Turbuhaler®, Budesonide pMDI, the Combination of Formoterol Turbuhaler® and Budesonide pMDI, and Placebo in COPD Patients
Phase 3
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2009-03-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1500
- Registration Number
- NCT00206154
- Locations
- 🇿🇦
Research Site, Umkomaas, South Africa
© Copyright 2025. All Rights Reserved by MedPath